Anorectics

Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Medical specialties, Clinical medicine, Nutrition, Bariatrics, Anorectics, Peptides, Setmelanotide, Obesity, Disease, Rare disease, Genetic disorder

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide with five new planned Phase 2 and 3 clinical trials. Rhythm will review these updates on its second quarter 2021 financial results and business update conference call today at 8 a.m. ET.

Key Points: 
  • We are excited to announce the significant expansion of our development program for setmelanotide.
  • These rare genetic diseases of obesity are serious, life-threatening diseases that affect children with early-onset, severe obesity.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Retrieved on: 
Tuesday, July 27, 2021
Medicine, Clinical medicine, Medical specialties, Anorectics, Breakthrough therapy, Peptides, Setmelanotide, Obesity, Rare disease, Disease

ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.
  • A webcast of the call will also be available under Events & Presentations in the Investor Relations section of the Rhythm website at ir.rhythmtx.com.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older

Retrieved on: 
Friday, July 23, 2021
Health, Diabetes, Other Health, General Health, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Anorectics, Exenatide, COVID-19 vaccines, Anti-diabetic drugs, Peptide hormones, Diabetes, Thrombocytopenia, Glucagon-like peptide-1, Oxford–AstraZeneca COVID-19 vaccine

This is the first completed trial of a once-weekly GLP-1 RA in a pediatric population with T2D.

Key Points: 
  • This is the first completed trial of a once-weekly GLP-1 RA in a pediatric population with T2D.
  • Safety and effectiveness of exenatide extended-release have not been established in pediatric patients less than 10 years of age.
  • If this occurs, patients should discontinue BYDUREON BCise and promptly seek medical advice
    Drug-induced, immune-mediated thrombocytopenia and associated bleeding has been reported with exenatide.
  • Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.

Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel

Retrieved on: 
Thursday, July 22, 2021
Life sciences, Health sciences, Health care, Pharmaceutical industry, Biotechnology, Anorectics, MC4, Biopharmaceutical, Medication, Setmelanotide

IMCIVREE perfectly fits in our portfolio of novel medicines, and we look forward to providing patients and physicians with this much-needed treatment.

Key Points: 
  • IMCIVREE perfectly fits in our portfolio of novel medicines, and we look forward to providing patients and physicians with this much-needed treatment.
  • As an MC4 receptor agonist, IMCIVREE is designed to restore impaired MC4 receptor pathway activity arising due to genetic deficits upstream of the MC4 receptor.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Medison is a global pharma company focusing on commercializing highly innovative therapies for patients in international markets.

Global Legal Cocaine Market Report 2021-2025 - Growing Demand for Pharmaceutical-grade Cocaine and Rising Number of Countries Decriminalizing and Legalizing Cocaine - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Legal, Professional services, Psychoactive drugs, Drugs, Branches of biology, Anorectics, Cocaine, Stimulants, Teratogens, Coca

The "Global Legal Cocaine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The publisher has been monitoring the legal cocaine market and it is poised to grow by 2.47 thousand oz during 2021-2025, progressing at a CAGR of almost 4%
    The market is driven by the growing demand for pharmaceutical-grade cocaine and the rising number of countries decriminalizing and legalizing cocaine.
  • The report on the legal cocaine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • This study identifies the growth in the trade of legal cocaine as one of the prime reasons driving the legal cocaine market growth during the next few years.

Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes

Retrieved on: 
Friday, June 25, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Organ systems, Hormones, Peptide hormones, Branches of biology, Anti-diabetic drugs, Anorectics, Diabetes, Exenatide, G protein-coupled receptors, Glucagon-like peptide-1 receptor agonist, Glucagon-like peptide-1, Glucagon

This Phase III trial is the first and only completed trial of a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in adolescents aged 1017 with T2D.

Key Points: 
  • This Phase III trial is the first and only completed trial of a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in adolescents aged 1017 with T2D.
  • James Ruggles, BYDUREON Medical Lead, said: Were greatly encouraged by these results in adolescents with type 2 diabetes.
  • We hope that, once approved, exenatide once weekly will serve as a much needed convenient treatment option for adolescent patients.
  • Consequently, once weekly injections of exenatide could fill that gap in treatment options for T2D patients in this age group.

22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives

Retrieved on: 
Friday, June 25, 2021
Psychoactive drugs, Nicotinic agonists, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Teratogens, Tobacco, True

It has now been just over one year since I was appointed CEO of 22nd Century Group, and I would like to thank you for your enthusiasm and support of our Company.

Key Points: 
  • It has now been just over one year since I was appointed CEO of 22nd Century Group, and I would like to thank you for your enthusiasm and support of our Company.
  • Shares of 22nd Century have soared over 470% in the past 12 months.
  • The new technology provides 22nd Century with a rapid pathway to introduce reduced nicotine traits into virtually all varieties of tobacco.
  • 22nd Century has reached a true inflection point in our business -- and the best is yet to come.

PANTHERx® Rare Pharmacy Selected by Rhythm Pharmaceuticals to Distribute IMCIVREE™ (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

Retrieved on: 
Thursday, June 24, 2021
Medical specialties, Branches of biology, Clinical medicine, Anorectics, Breakthrough therapy, Peptides, Setmelanotide, Proopiomelanocortin, Leptin, Obesity, Pharmacy, Proprotein convertase 1

PITTSBURGH, June 24, 2021 /PRNewswire/ --PANTHERx Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE (setmelanotide).

Key Points: 
  • PITTSBURGH, June 24, 2021 /PRNewswire/ --PANTHERx Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE (setmelanotide).
  • People living with obesity due to POMC, PCSK1 or LEPR deficiency struggle with extreme, insatiable hunger beginning at a young age, resulting in early-onset, severe obesity.
  • PANTHERx Rare Pharmacy, part of Envolve Pharmacy Solutions, is one of the largest and fastest growing rare pharmacies in the United States.
  • IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing.

Government of Canada helping communities address rising methamphetamine use

Retrieved on: 
Thursday, June 17, 2021
Psychoactive drugs, Drugs, Anorectics, Management of obesity, Methamphetamine, Phenethylamines, Stimulants, Legal status of methamphetamine

The Government of Canada is deeply concerned about this increased use and the risks it poses to the health and safety of people who use methamphetamine, and their communities.

Key Points: 
  • The Government of Canada is deeply concerned about this increased use and the risks it poses to the health and safety of people who use methamphetamine, and their communities.
  • The Government of Canada continues to work with all levels of government, partners, stakeholders, people with lived and living experience and organizations in communities across the country to prevent harms associated with substance use.
  • Together with these organizations, we are helping to provide targeted supports and resources for people using methamphetamine, including those that are specific to Indigenous communities, youth and under-served rural communities."
  • A 2019 study on the impacts of methamphetamine found some Indigenous communities across Canada are increasingly reporting significant health and safety issues related to methamphetamine use.

Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

Retrieved on: 
Thursday, June 10, 2021
Health, Clinical trials, General Health, Research, Pharmaceutical, Science, Psychoactive drugs, Smoking, Electronic cigarettes, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Addiction, Effects of nicotine on human brain development, Tobacco Use Disorders, Omeros Corporation, TOBACCO USE DISORDERS, OMEROS CORPORATION

Specifically, inhibitors of PDE7 reduced nicotine consumption and relapse in rodent models of nicotine abuse.

Key Points: 
  • Specifically, inhibitors of PDE7 reduced nicotine consumption and relapse in rodent models of nicotine abuse.
  • The research was conducted in collaboration with the School of Pharmacy of the University of Camerino in Italy.
  • Recent developments such as forms of electronic nicotine delivery are contributing to a new surge of nicotine use, especially in young adults.
  • Omeros owns global rights to the use of PDE7 inhibitors for the treatment of addictive disorders.